Effect of Valproic Acid Concentration on Photic Response
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00609245|
Recruitment Status : Completed
First Posted : February 6, 2008
Results First Posted : June 14, 2017
Last Update Posted : June 14, 2017
|Condition or disease||Intervention/treatment||Phase|
|Photosensitive Epilepsy||Drug: Valproic Acid Drug: Placebo||Phase 4|
Photosensitive epilepsy is a form of epilepsy that is considered to have a genetic basis in most instances. It is a reflex type of epilepsy. Patients with this condition exhibit epileptic activity patterns (called photoparoxysmal response-PPR) on their EEG during intermittent photic stimulation with certain flash frequencies.
- To determine the extent of the pharmacodynamic effect of small changes in total and free VPA concentration via constant infusion of intravenous sodium valproate within the same photosensitive epilepsy patient.
- To determine the change in total and free VPA concentration required to achieve maximal effect on PPR in patients with photosensitive epilepsy.
- Valproic acid (VPA) demonstrates differential pharmacodynamic effect on PPR with small changes in VPA concentration (5-20 mg/L changes in total, or 0.5 to 2 mg/L changes in free VPA) within the same patient. In essence, the VPA concentration-response curve in patients with photosensitive epilepsy is relatively steep.
- Intravenously-administered VPA will demonstrate a reduction in standard photosensitive range (SPR) or abolition of PPR for at least 80% of patients studied, when the entire range of free VPA concentrations is considered.
Photosensitivity, defined as a PPR on intermittent photic stimulation (IPS), is found in approximately 5% of all epileptic patients. Markedly photosensitive patients are usually sensitive to IPS within clearly defined limits of flash frequency (mostly between 10-30 Hz). This photosensitivity range, the difference between the highest and lowest flash rates that consistently elicit a photoparoxysmal response (PPR), can be used as a quantitative measure of photosensitivity.
Administration of some antiepileptic drugs (AEDS) can diminish or even abolish PPR. With a standard set of tested frequencies, a standard photosensitive range (SPR) can be used to measure drug effect on photosensitivity. Combined with blood level monitoring, the model offers information about actual pharmacodynamic effect as measured with IPS related to the changes in blood levels.
The standardized IPS procedure includes delivery of short (5 second-) trains of flashes. The stimulation starts with the lowest frequencies (which usually do not produce a PPR) only up to the limits of the photosensitivity range (the threshold frequencies for which the patient shows an epileptiform EEG response). After that the stimulation starts again with the highest frequencies (which also do not produce a PPR) down to the frequency that produces a definite PPR.
The photic stimulator will be manually controlled for all stimulations in order to abort the stimulation when a clear PPR is elicited. With all stimulations, there is simultaneous recording of the EEG and direct observation of the patient for clinical changes. With all the safety measures in place, the likelihood of provoking prominent clinical seizures is extremely low.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||13 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effect of Small Changes in Plasma Valproic Acid Concentration on the Photoparoxysmal Response|
|Study Start Date :||December 2007|
|Actual Primary Completion Date :||December 2008|
|Actual Study Completion Date :||December 2008|
U.S. FDA Resources
Experimental: Placebo then Valproic Acid (VPA)
all patients will have placebo on day 1 and VPA infusion on day 2
Drug: Valproic Acid
The investigators will utilize intravenous sodium valproate at visit 3. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003).
Other Name: DepaconDrug: Placebo
Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration at visit 2.
Other Name: Normal Saline (NS) and 5% Dextrose in water (D5W)
- Difference in SPR During Placebo and VPA Infusions [ Time Frame: At the start of EEG monitoring/drug infusion, and on an hourly basisfor 12 hours ]standard photosensitive range (SPR) Each participant is exposed to intermittent photic stimulation at 14 predetermined frequencies in order to detect changes in response around typical upper and lower frequency thresholds (e.g., 2 Hz, 5 Hz, 8Hz, 10 Hz, etc.). Each flash frequency that elicits a photosensitive response is considered one "step", and the result is transformed into a metric called the standardized photosensitive range (SPR). The SPR ranges from 0 to 14, where each point represents the number of flash frequencies that elicited a photosensitive response.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00609245
|United States, Missouri|
|The Comprehensive Epilepsy Care Center for Children & Adults|
|Chesterfield, Missouri, United States, 63017|
|United States, Tennessee|
|Nashville, Tennessee, United States, 37232|
|Principal Investigator:||Bassel Abou-Khalil, MD||Vanderbilt University|
|Principal Investigator:||William Rosenfeld, MD||The Comprehensive Epilepsy Care Center for Children & Adults|
|Principal Investigator:||Dorothee Kasteleijn-Nolst Trenite, MD, PhD||The Comprehensive Epilepsy Care Center for Children & Adults|